← Back to Search

Immunomodulator

Abatacept for Interstitial Lung Disease (ATtackMy-ILD Trial)

Phase 2
Waitlist Available
Research Sponsored by Rohit Aggarwal, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Medication Washout Period methotrexate 4 weeks Other IS agent (e.g. azathioprine, cyclosporine, tacrolimus, leflunomide, mycophenolate mofetil) 4 weeks IVIg or cyclophosphamide 3 months rituximab 6 months infliximab or adalimumab 8 weeks glucocorticoids 2 weeks etanercept 2 weeks anakinra 1 week pirfenidone 4 weeks
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights

ATtackMy-ILD Trial Summary

This trial is testing whether a drug called Abatacept can treat interstitial lung disease associated with the anti-synthetase syndrome.

Eligible Conditions
  • Interstitial Lung Disease
  • Myositis

ATtackMy-ILD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
If you are taking certain medications, you must stop taking them for a specific amount of time before participating in the study: - Methotrexate: 4 weeks - Other immunosuppressive agents (e.g. azathioprine, cyclosporine, tacrolimus, leflunomide, mycophenolate mofetil): 4 weeks - IVIg or cyclophosphamide: 3 months - Rituximab: 6 months - Infliximab or adalimumab: 8 weeks - Glucocorticoids: 2 weeks - Etanercept: 2 weeks - Anakinra: 1 week - Pirfenidone: 4 weeks

ATtackMy-ILD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Vital capacity
Secondary outcome measures
Dyspnea
Time to improvement in FVC% by ≥10
Time to progression free survival where progression

Side effects data

From 2023 Phase 3 trial • 613 Patients • NCT03086343
6%
URINARY TRACT INFECTION
5%
UPPER RESPIRATORY TRACT INFECTION
5%
NASOPHARYNGITIS
3%
HYPERTENSION
100%
80%
60%
40%
20%
0%
Study treatment Arm
Abatacept
Upadacitinib 15 mg

ATtackMy-ILD Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AbataceptExperimental Treatment1 Intervention
Subcutaneous injection of abatacept 125 mg weekly for 24 weeks. 24 week optional follow up phase all subjects receive abatacept 125 mg weekly.
Group II: PlaceboPlacebo Group1 Intervention
Subcutaneous placebo injection weekly for 24 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Abatacept
2005
Completed Phase 4
~112150

Find a Location

Who is running the clinical trial?

Rohit Aggarwal, MDLead Sponsor
2 Previous Clinical Trials
146 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,638 Previous Clinical Trials
4,128,494 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people will be given lenalidomide in this experiment?

"This particular clinical trial is no longer recruiting patients. It was first posted on June 1st, 2017 and last updated on October 31st, 2022. However, there are currently 326 trials for myositis and 36 trials for Abatacept that are still enrolling patients."

Answered by AI

What is the total number of research facilities participating in this project?

"Patients can be enrolled at this clinical trial at Brigham & Women's Hospital in Boston, Cedars-Sinai Medical Center in Beverly Hills, John Hopkins Medical Center in Baltimore. Including these 5 additional sites, there are a total of 10 locations where patients can enroll."

Answered by AI

To what condition does Abatacept lend itself as a treatment?

"Abatacept is an effective intervention for patients experiencing rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis."

Answered by AI

Could you please list any other research studies that have used Abatacept?

"Abatacept was first researched in 2007 by University of Nebraska Medical Center. Since that time, there have been a total of 18370 completed studies on the topic. Right now, there are 36 trials underway with some taking place in Boston, Massachusetts."

Answered by AI

Has the Abatacept drug been federally approved in the USA?

"Abatacept's safety is estimated to be a 2. This is due to the fact that it is still in Phase 2 trials, meaning while there are some studies that support its safety, none have been able to confirm its efficacy."

Answered by AI

Are there any more slots open for willing participants in this research?

"The clinical trial in question is not currently active, based on information from the website. This particular study was first posted on June 1st, 2017 and was last edited on October 31st, 2022. There are, however, 362 other trials that are looking for patients right now."

Answered by AI
Recent research and studies
~3 spots leftby Apr 2025